latozinemab

News

Alector has abandoned latozinemab as a treatment for frontotemporal dementia, four years after GSK licensed the antibody in a $700m upfront deal.

News

Patients in the EU with the ultra-rare disease WHIM syndrome now have their first approved treatment, Norgine's Xolremdi.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.